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Abstract
Recent studies investigating the pharmacological management of neuropathic pain support the
efficacy of certain antidepressants, anticonvulsants, and opioids. Novel directions in drug applications
include topical applications of patches with either lidocaine or capsaicin and intradermal injections of
botulinum toxin. In cases of partial pain relief, drug combinations may be considered.
Introduction and context
Neuropathic pain is a heterogeneous group of chronic
pain conditions caused by lesion or disease of the
peripheral or central nervous system [1]. Common
neuropathic pain syndromes include painful polyneuro-
pathy (e.g., due to diabetes), postherpetic neuralgia,
peripheral nerve injury, radiculopathy, cancer-related
pain, and central post-stroke pain. Neuropathic pain
often has a negative impact on the mental health and
quality of life in these groups of patients. Recommended
first-line treatments are the anticonvulsants gabapentin
and pregabalin, certain antidepressants (tricyclic anti-
depressants [TCAs] or serotonin-noradrenaline reuptake
inhibitors [SNRIs]), and topical lidocaine [2,3]. Patients
may, however, experience no or only partial pain
reduction in tolerated doses.
Recent advances
Anticonvulsants and antidepressants
Different types of neuropathic pain may respond
differently to a given drug and there is a need for studies
where predictive factors for response are identified. In a
recent well-designed randomized controlled trial (RCT),
gabapentin in doses up to 2400 mg/day failed to relieve
pain in patients with post-traumatic or post-operative
nerve injury [4], although the study showed marked
improvement on several secondary outcome measures,
including pain relief and Patient Global Impression of
Change. Also, flexible-dose regimes of pregabalin seem
to provide a better combination of pain relief and few
discontinuations than a fixed dose regime [5].
Levetiracetam is a novel anti-epileptic drug that binds to
the synaptic vesicle protein SV2A in the brain and spinal
cord. Despite the antinociceptive effect found in animal
models of neuropathic pain, levetiracetam did not
relieve post-mastectomy syndrome and spinal cord
injury pain [6,7].
The need for mechanism-based approaches and identi-
fication of possible predictors for response is also
relevant for sodium channel blockers. Except for the
use of sodium channel blockers in trigeminal neuralgia,
where they are first-line medication, there is limited
evidence for efficacy of drugs like oxcarbazepine,
lamotrigine, and the newer anticonvulsant lacosamide
[2,8,9] in neuropathic pain. However, despite the lack
of an overall effect in large-scale trials, subgroups of
patients do seem to respond.
Studies with head-to-head comparisons find only
minor differences in efficacy between TCAs and
gabapentin/pregabalin [10]. SNRIs are also effective
in patients with painful polyneuropathy [11] and can
be an alternative to TCAs, in particular in patients with
cardiac disorders. Selective serotonin reuptake inhibi-
tors provide a clinically meaningful effect in only few
patients [12].
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Opioids also have a role in the treatment of neuropathic
pain. Their efficacy is comparable to that of gabapentin/
pregabalin and TCAs [2,13,14], but they are not
considered first-line drugs due to side effects, tolerance,
uncertain long-term safety and efficacy, and so on.
Combination therapy
In cases of partial but insufficient pain relief by a single
drug, combinations are often used. Due to a lack of
controlled studies, the rationale for such combination
therapy has mainly been based on theory, but is now
supported by recent RCTs. The best evidence is for the
combination of a TCA or an opioid with gabapentin
[15-17]. Such combinations are suggested to improve
treatment compared with treatment with each drug alone
in maximum tolerated doses.
New drug classes
Topical lidocaine is a safe treatment with no or limited
systemic side effects. New evidence from an open-label
study suggests that lidocaine patches are useful, not only
in postherpetic neuralgia or very localized neuropathic
pain but also in painful diabetic neuropathy [18].
Transient receptor TRPV1 agonists and antagonists
represent a new class of analgesics [19]. A single
application of a high-concentration capsaicin dermal
patch produced sustained pain reductionin patients with
postherpetic neuralgia [20] and painful HIV-associated
sensory polyneuropathy [21], although the long-term
effect and the frequency of treatments have not been
examined. NGX-4010 (marketed name Qutenza
®), a
cutaneous patch of capsaicin 8%, has been given
marketing authorization in Europe. The approved
indication is: “treatment of peripheral neuropathic pain
in non-diabetic adults”. NGX-4010 treatments may be
repeated every 90 days.
Botulinum toxin type A (BTX-A) given intradermally is
another novel topical treatment approach that has been
shown to relieve focal painful neuropathy [22], and
painful diabetic polyneuropathy in two RCTs [23].
Patients received multiple intradermal injections once
in the affected area and the pain reduction lasted for 12
weeks. Large-scale trials and examination of long-term
efficacy are needed to test its value for clinical practice.
A phase 2 RCT found that the neuronal nicotinic
acetylcholine receptor agonist ABT-594 significantly
reduced pain intensity compared with placebo in
patients with painful diabetic neuropathy [24]. Unfortu-
nately, ABT-594 treatment was associated with a high
number of intolerable dose-related side effects, but the
study suggests that further development of this drug class
may present new therapeutic options.
Implications for clinical practice
The best available evidence and knowledge of side-effect
profiles still support the current guidelines of using TCAs
(or alternatively SNRIs), gabapentin, and pregabalin as
first-line therapy and opioids as second line therapy for
neuropathic pain. The side-effect profile for opioids is
judgeddifferentlybysomeresearchers,whichmayexplain
why opioids are considered by some as first-line therapy
for certain conditions. In order to minimize side effects,
recent advances have led to the development of topical
agents,includinglidocainepatches,NGX-4010(high-dose
capsaicin), and intradermal BTX-A. There is not abundant
evidence for these treatments, but their advantage is that
they have no or only minor systemic side effects.
If one drug provides only partial pain relief, a combina-
tion with another drug class is recommended – for
example, an antidepressant or an opioid in combination
with gabapentin or pregabalin, or a combination of a
topical agent with an oral drug.
Carbamazepine, oxcarbazepine, lamotrigine, and lacosa-
midehavenoprimaryroleinthetreatmentofneuropathic
pain (except for trigeminal neuralgia),but whether wecan
identify subgroups of patients with specific symptoms or
signs who will benefit from these treatments is still to be
determined. This emphasizes the need for a mechanism-
based approach, where patients are classified based on
constellations of symptoms and signs rather than a
disease-based classification. Hopefully, this will lead to
better patient-oriented treatment. Levetiracetam does not
seem to have a role in the treatment of neuropathic pain.
Abbreviations
BTX-A, botulinum toxin type A; RCT, randomized
controlled trial; SNRI, serotonin noradrenaline reuptake
inhibitor; TCA, tricyclic antidepressant.
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